Equities analysts forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will announce earnings of $0.26 per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.19 and the highest is $0.33. Supernus Pharmaceuticals also reported earnings of $0.26 per share in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.07 per share for the current fiscal year, with EPS estimates ranging from $1.01 to $1.15. For the next year, analysts anticipate that the company will post earnings of $1.49 per share, with EPS estimates ranging from $1.25 to $1.72. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. Supernus Pharmaceuticals’s quarterly revenue was up 41.5% compared to the same quarter last year.

Several equities analysts have recently weighed in on the company. Jefferies Group reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. SunTrust Banks reiterated a “buy” rating and set a $61.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. Janney Montgomery Scott reiterated a “hold” rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Finally, B. Riley reiterated a “buy” rating and set a $50.00 target price on shares of Supernus Pharmaceuticals in a report on Monday, November 20th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $49.60.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the sale, the senior vice president now directly owns 12,500 shares in the company, valued at approximately $623,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 150,000 shares of company stock worth $7,055,350. Company insiders own 6.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in Supernus Pharmaceuticals by 0.5% during the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after purchasing an additional 31,331 shares during the last quarter. Vanguard Group Inc. increased its holdings in Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. State Street Corp increased its holdings in Supernus Pharmaceuticals by 3.1% during the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after purchasing an additional 42,165 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in Supernus Pharmaceuticals by 24.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after purchasing an additional 267,971 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Supernus Pharmaceuticals by 10.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after purchasing an additional 122,042 shares during the last quarter. Institutional investors own 98.47% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded down $0.60 during midday trading on Tuesday, hitting $37.20. The stock had a trading volume of 511,359 shares, compared to its average volume of 609,626. The firm has a market cap of $1,910.00, a price-to-earnings ratio of 36.93, a P/E/G ratio of 1.66 and a beta of 1.30. Supernus Pharmaceuticals has a fifty-two week low of $20.70 and a fifty-two week high of $50.04.

COPYRIGHT VIOLATION WARNING: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/01/brokerages-expect-supernus-pharmaceuticals-inc-supn-will-post-earnings-of-0-26-per-share.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.